Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2014

View Archived Issues

Novel association found for intracranial aneurysm susceptibility

Cardioxyl Pharmaceuticals begins first trial of CXL-1427

Roche discloses novel protein ligase inhibitors for cancer

Daiichi Sankyo discloses new agents for bacterial infections

Novel thrombin inhibitors prepared at Merck & Co.

Emory University patents new NMDA receptor modulators

Amgen divulges novel TRPM8 antagonists for migraine

Long-term analysis of a prognostic gene signature for breast cancer

NICE publishes final guidance recommending Eylea in England

Known cognition enhancer active in models of neuropathic pain

Application for approval of an oral disintegrating tablet formulation

Critical Outcome Technologies signs letter of intent with Portage Biotech for COTI-2

Treatment under way in phase IIb study of brilacidin for ABSSSI

Orexigen Therapeutics receives European CHMP questions on NB-32 MAA

Bexsero available in Canada

NICE final guidance recommends Pixuvri for relapsed/refractory B-cell NHL

Phase I study of tuberculosis vaccine DAR-901 opens

Dosing completed in phase II trial of Zoenasa for ulcerative colitis

Multifunctional polynitroxylated albumin for the early treatment of stroke

Chinese researchers synthesize new PI3Kdelta inhibitors

CytoVac initiates phase II study of ALECSAT for glioblastoma multiforme

InDex Pharmaceuticals closes new rights issue

NeRRe Therapeutics initiates phase II study of orvepitant for EGFR inhibitor-induced pruritus

Mast Therapeutics opens international enrollment in EPIC study of MST-188

Adocia reports preliminary results from phase I/II trial of BioChaperone Combo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...